SWOG clinical trial number
SWOG-9109

Neoadjuvant Zoladex and Flutamide in Bulky and Non-Bulky Clinical Stage C Carcinoma of the Prostate, Phase II

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Local Prostate
Activated
12/01/1993
Closed
10/15/1996

Research committees

Genitourinary Cancer

Treatment

Goserelin Acetate

Publication Information Expand/Collapse

2012

Ten year follow-up of neoadjuvant therapy with goserelin acetate and flutamide prior to radical prostatectomy for clinical T3/T4 prostate cancer: update on Southwest Oncology Group study 9109

RK Berglund;C Tangen;IJ Powell;BA Lowe;GP Haas;PR Carroll;ED Canby-Hagino;RW de Vere White;GP Hemstreet;ED Crawford;IM Thompson;E Klein Urology 79(3):633-637

PMid: PMID22386416 | PMC number: PMC3839235

2002

Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5 year follow-up, phase II SWOG study 9109

IJ Powell;CM Tangen;GJ Miller;BA Lowe;G Haas;PR Carroll;MB Osswald;R deVere-White;IM Thompson Jr;ED Crawford Journal of Urology 168:2016-2019

2001

Neoadjuvant zoladex and flutamide in bulky and non-bulky clinical stage C carcinoma of the prostate

IJ Powell;CM Tangen;GP Haas;D Crawford;GJ Miller;BA Lowe;IM Thompson Journal of Urology 165(5)Suppl:330(#1355)

Other Clinical Trials

SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase